Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T 1H-MRS Study

Background Glutathione (GSH), a major intracellular antioxidant, plays a role in NMDA receptor-mediated neurotransmission, which is involved in the pathophysiology of schizophrenia. In the present study, we aimed to investigate whether GSH levels are altered in the posterior medial frontal cortex of schizophrenic patients. Furthermore, we examined correlations between GSH levels and clinical variables in patients. Methods and Findings Twenty schizophrenia patients and 16 age- and gender-matched normal controls were enrolled to examine the levels of GSH in the posterior medial frontal cortex by using 3T SIGNA EXCITE 1H-MRS with the spectral editing technique, MEGA-PRESS. Clinical variables of patients were assessed by the Global Assessment of Functioning (GAF), Scale for the Assessment of Negative Symptoms (SANS), Brief Psychiatric Rating Scale (BPRS), Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS), and five cognitive performance tests (Word Fluency Test, Stroop Test, Trail Making Test, Wisconsin Card Sorting Test and Digit Span Distractibility Test). Levels of GSH in the posterior medial frontal cortex of schizophrenic patients were not different from those of normal controls. However, we found a significant negative correlation between GSH levels and the severity of negative symptoms (SANS total score and negative symptom subscore on BPRS) in patients. There were no correlations between brain GSH levels and scores on any cognitive performance test except Trail Making Test part A. Conclusion These results suggest that GSH levels in the posterior medial frontal cortex may be related to negative symptoms in schizophrenic patients. Therefore, agents that increase GSH levels in the brain could be potential therapeutic drugs for negative symptoms in schizophrenia.

[1]  S. Mukherjee,et al.  Free radical pathology and antioxidant defense in schizophrenia: a review , 1996, Schizophrenia Research.

[2]  S. Harada,et al.  Glutathione S-transferase M1 gene deletion may be associated with susceptibility to certain forms of schizophrenia. , 2001, Biochemical and biophysical research communications.

[3]  K. Hashimoto,et al.  Effect of antioxidant N-acetyl-l-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine , 2004, Brain Research.

[4]  T. Werge,et al.  Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence , 2007, Proceedings of the National Academy of Sciences.

[5]  Matcheri S. Keshavan,et al.  Insight and frontal cortical function in schizophrenia: A review , 2006, Schizophrenia Research.

[6]  K. Hashimoto,et al.  Glutamate Hypothesis of Schizophrenia and Approach for Possible Therapeutic Drugs , 2004 .

[7]  D. Matsuzawa,et al.  Association study between polymorphisms in glutathione‐related genes and methamphetamine use disorder in a Japanese population , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[8]  T. Satoh,et al.  Contribution of reduced and oxidized glutathione to signals detected by magnetic resonance spectroscopy as indicators of local brain redox state , 2006, Neuroscience Research.

[9]  T. Kosten,et al.  Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. , 2007, The Journal of clinical psychiatry.

[10]  R. Rodriguiz,et al.  Monoaminergic dysregulation in glutathione-deficient mice: Possible relevance to schizophrenia? , 2005, Neuroscience.

[11]  Ömer Akyol,et al.  The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients The possible role of oxidant/antioxidant imbalance , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[12]  J. Coyle,et al.  The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. , 2001, The American journal of psychiatry.

[13]  Rolf Gruetter,et al.  Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference‐edited spectra , 2003, Magnetic resonance in medicine.

[14]  Jeffrey K. Yao,et al.  Human plasma glutathione peroxidase and symptom severity in schizophrenia , 1999, Biological Psychiatry.

[15]  S. Strakowski,et al.  Persistent attentional dysfunction in remitted bipolar disorder. , 2001, Bipolar disorders.

[16]  D. Wedding.  Halstead‐Reitan Neuropsychological Test Battery , 2010 .

[17]  Tomiki Sumiyoshi,et al.  Disorganization of semantic memory underlies alogia in schizophrenia: An analysis of verbal fluency performance in Japanese subjects , 2005, Schizophrenia Research.

[18]  C. Frith,et al.  Meeting of minds: the medial frontal cortex and social cognition , 2006, Nature Reviews Neuroscience.

[19]  K. Hashimoto,et al.  Protective Effects of N-acetyl-L-cysteine on the Reduction of Dopamine Transporters in the Striatum of Monkeys Treated with Methamphetamine , 2004, Neuropsychopharmacology.

[20]  S. Mukherjee,et al.  Enzymes of the antioxidant defense system in chronic schizophrenic patients , 1991, Biological Psychiatry.

[21]  Reto Meuli,et al.  Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients , 2008, Neuropsychopharmacology.

[22]  K. Uğurbil,et al.  Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia , 2005, Magnetic Resonance Materials in Physics, Biology and Medicine.

[23]  G. Chazot,et al.  Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[24]  Ravinder Reddy,et al.  Altered Glutathione Redox State in Schizophrenia , 2005, Disease markers.

[25]  C. Tamminga,et al.  Schizophrenia and glutamatergic transmission. , 1998, Critical reviews in neurobiology.

[26]  Jonathan D. Cohen,et al.  Interference and Facilitation Effects during Selective Attention: An H2 15O PET Study of Stroop Task Performance , 1995, NeuroImage.

[27]  August G. Wang,et al.  Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. , 2006, American journal of human genetics.

[28]  D. Matsuzawa,et al.  A functional glutathione S‐transferase P1 gene polymorphism is associated with methamphetamine‐induced psychosis in Japanese population , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[29]  H. Monyer,et al.  NMDA receptor channels: Subunit-specific potentiation by reducing agents , 1994, Neuron.

[30]  D. Matsuzawa,et al.  Functional Polymorphism of the Glutathione Peroxidase 1 Gene Is Associated with Personality Traits in Healthy Subjects , 2005, Neuropsychobiology.

[31]  J. Barth,et al.  The Halstead-Reitan Neuropsychological Test Battery. , 2000 .

[32]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[33]  Z. Jenei,et al.  Glutathione Is an Endogenous Ligand of Rat Brain N-Methyl-D-Aspartate (NMDA) and 2-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionate (AMPA) Receptors , 1997, Neurochemical Research.

[34]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[35]  S. Lipton,et al.  Redox modulatory site of the NMDA receptor–channel complex: Regulation by oxidized glutathione , 1991, Journal of neuroscience research.

[36]  C. Schroeder,et al.  Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Serretti,et al.  Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population , 2004, Psychiatric genetics.

[38]  Kenji Hashimoto,et al.  Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. , 2003, Archives of general psychiatry.

[39]  P Boesiger,et al.  Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo , 2000, The European journal of neuroscience.

[40]  Etelvino J. H. Bechara,et al.  Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. , 1986, Clinical chemistry.